Logo

BTTC

Black Titan Corporation

BTTC

Black Titan Corporation • NASDAQ
$3.08 ▼ -1.48% (-0.05)
Market Cap $23.82 M
52w High $39.00
52w Low $2.81
Dividend Yield 0%
P/E 61.67
Volume 3.20K
Outstanding Shares 7.72M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.78B ▲ $-1.795B ▼ 0% $-0.47 ▼ $0 ▲
Q2-2025 $0 $657K ▲ $-689K ▼ 0% $-0.16 ▲ $-689K ▼
Q1-2025 $0 $534K ▼ $-563K ▲ 0% $-0.17 ▲ $-563K ▲
Q4-2024 $0 $666K ▼ $-790K ▼ 0% $-0.54 ▼ $-790K ▼
Q3-2024 $0 $754K $-763K 0% $-0.001 $-763K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $74.087M ▲ $23.229B ▲ $3.34B ▲ $19.889B ▼
Q2-2025 $21.344M ▲ $23.156B ▲ $2.622B ▲ $20.535B ▲
Q1-2025 $1.945M ▲ $2.156M ▼ $279K ▼ $1.877M ▲
Q4-2024 $371.963K ▼ $2.219M ▼ $1.214M ▲ $1.004M ▼
Q3-2024 $3.399M $3.602M $371K $3.231M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.795B ▼ $-326.782M ▼ $0 $379.525M ▲ $52.743M ▲ $-326.782M ▼
Q2-2025 $-821.409M ▼ $-317.456M ▼ $0 $242.315M ▲ $-75.141M ▼ $-317.456M ▼
Q1-2025 $-563K ▲ $-867K ▼ $0 $-19K ▲ $-886K ▼ $-867K ▼
Q4-2024 $-790K ▼ $-506K ▲ $0 $-62K ▼ $-568K ▲ $-506K ▲
Q3-2024 $-763K $-693K $0 $0 $-692.999K $-693K

Five-Year Company Overview

Income Statement

Income Statement There is very little usable income statement history here. Reported sales are essentially absent, and past results appear driven more by one‑off items and legacy write‑downs than by a stable business. The big swings in past earnings per share hint at a company that has been restructuring and absorbing losses rather than running a mature, steady operation. Going forward, the key story is less about what they have earned so far and more about whether the merged group can turn its consulting and pharma assets, plus the new crypto push, into a clear, repeatable source of revenue and profit.

Balance Sheet

Balance Sheet The balance sheet data disclosed is minimal, so it is hard to judge the company’s financial strength, borrowing levels, or asset base with confidence. Historically, Titan Pharmaceuticals was a small development‑stage firm, and TalenTec was an operating services business, so the combined group likely has a mix of intangible drug technology, consulting contracts, and modest physical assets. Until fuller post‑merger figures are available, investors are effectively in the dark on leverage, liquidity, and capital cushion.

Cash Flow

Cash Flow Cash flow information is basically missing, which matters a lot for a company in transition. The pharma side likely consumed cash in research and overhead, while the consulting arm should generate more predictable inflows. The new digital asset strategy could add further volatility, because crypto investments and mining can swing cash needs sharply with market conditions. Right now, there is not enough disclosed to tell whether the business is self‑funding or reliant on fresh capital to pursue its plans.

Competitive Edge

Competitive Edge Black Titan’s competitive position is fragmented. The ProNeura drug‑delivery technology sits in a narrow biotech niche with potential scientific differentiation but unclear commercial traction since the main product was withdrawn. TalenTec, on the other hand, is an established human capital management consultant in Asia‑Pacific with recognized software partnerships and sticky client relationships. The new crypto and digital asset push does not yet come with a clearly defined edge versus many specialized competitors in that space. Overall, the company has pockets of strength, but no obvious, unified moat tying its three lines of business together.

Innovation and R&D

Innovation and R&D The most concrete innovation is the ProNeura drug‑delivery platform, which is backed by patents and experience in long‑acting implants for chronic conditions. This is genuine R&D‑driven technology with potential, though it still needs commercially viable programs to unlock value. TalenTec contributes more applied innovation in HR and workforce software implementation, including biometric attendance and cloud‑based HR systems, which are more incremental but revenue‑ready. The blockchain and crypto initiative is at the concept stage: leadership with crypto experience is in place, and the company is talking about mining, coin investments, and fintech deals, but there is little detail on proprietary technology, products, or timelines. The innovation story is therefore real but scattered, with most clarity on legacy pharma and HR tech rather than on the new digital asset vision.

Summary

Black Titan is an unusual, early‑stage conglomerate that blends a development‑stage drug platform, a mature HR/IT consulting business, and a yet‑to‑be‑defined crypto and digital asset arm. Historical financials provide limited guidance and suggest a business that has been restructuring and absorbing losses more than delivering steady earnings. The balance sheet and cash‑flow picture are not well disclosed, so financial resilience and funding needs remain uncertain. Strategically, the company owns some genuine technological and service assets, but these sit in separate silos with no obvious integration, while the high‑profile crypto pivot lacks concrete plans and proof points so far. The central questions are whether management can: clarify a cohesive strategy, show stable cash generation from consulting, reignite value from the drug‑delivery platform, and build a distinctive, not purely speculative, position in digital assets. Until those pieces become clearer, the story is more about potential and execution risk than about established financial performance.

NEWS

November 12, 2025 · 8:30 AM UTC

BLACK TITAN CORPORATION APPOINTS CZHANG LIN AS CO-CHIEF EXECUTIVE OFFICER

Read more

October 3, 2025 · 5:26 PM UTC

Titan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan Corporation

Read more